Current Psychiatry Reports

, Volume 12, Issue 5, pp 433–440 | Cite as

Comparison of Available Treatments for Tobacco Addiction

  • Aryeh I. Herman
  • Mehmet SofuogluEmail author


Cigarette smoking is a major public health problem that causes more than 5 million deaths annually worldwide. Cigarette smoking is especially common among individuals with psychiatric comorbidity, including individuals with primary psychiatric disorders and other addictions. Effective behavioral and pharmacologic treatments for smoking cessation are available. Behavioral treatments including brief (< 3 min) counseling by physicians are effective. Seven first-line pharmacologic treatments are currently available: five nicotine replacement therapies, bupropion, and varenicline. In addition, clonidine and nortriptyline are second-line treatments for smoking cessation. These treatments increase the chances of quitting smoking by two- to threefold, supporting their use in smokers who are motivated to quit. However, effective treatments for many subpopulations, including smokers with psychiatric comorbidities as well as adolescent, pregnant, or postpartum smokers, remain to be developed and represent an important challenge.


Nicotine Nicotine pharmacotherapy Special populations Tobacco use disorder Clinical trials Smoking cessation 



This research was supported by the Veterans Administration Mental Illness Research, Education, and Clinical Center and National Institute on Drug Abuse grants K02 DA021304 (to Dr. Sofuoglu) and K12 DA00167 (to Dr. Herman)


No potential conflicts of interest relevant to this article were reported.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Thorne SL, Malarcher A, Maurice E, Caraballo R: Cigarette smoking among adults—United States, 2007. JAMA 2009, 301:373–375.CrossRefGoogle Scholar
  2. 2.
    Grant BF, Hasin DS, Chou SP, et al.: Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004, 61:1107–1115.CrossRefPubMedGoogle Scholar
  3. 3.
    •• Fiore MC, Jaén CR, Baker TB, et al.: Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services, Public Health Service; 2008. The clinical practice guidelines are the main resource for treating individuals with tobacco use and dependence. The guidelines are based on the review of literature for most evidence-based treatments.Google Scholar
  4. 4.
    Le Foll B, Wertheim C, Goldberg SR: High reinforcing efficacy of nicotine in non-human primates. PLoS One 2007, 2:e230.CrossRefPubMedGoogle Scholar
  5. 5.
    • Sofuoglu M, Yoo S, Hill KP, Mooney M: Self-administration of intravenous nicotine in male and female cigarette smokers. Neuropsychopharmacology 2008, 33:715–720. Although nicotine is the main addictive chemical in tobacco, there have been few studies of pure nicotine self-administration in humans. This study showed that smokers self-administer intravenous nicotine doses that are within the range of those of average intake from cigarette smoking. This model may be useful in the evaluation of the effects of both behavioral and pharmacologic manipulations on nicotine self-administration in humans.CrossRefPubMedGoogle Scholar
  6. 6.
    Dani JA, Bertrand D: Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 2007, 47:699–729.CrossRefPubMedGoogle Scholar
  7. 7.
    Balfour DJ: The neuronal pathways mediating the behavioral and addictive properties of nicotine. Handb Exp Pharmacol 2009, 192:209–233.CrossRefPubMedGoogle Scholar
  8. 8.
    Quick MW, Lester RA: Desensitization of neuronal nicotinic receptors. J Neurobiol 2002, 53:457–478.CrossRefPubMedGoogle Scholar
  9. 9.
    Mansvelder HD, Keath JR, McGehee DS: Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 2002, 33:905–919.CrossRefPubMedGoogle Scholar
  10. 10.
    Mottillo S, Filion KB, Belisle P, et al.: Behavioural interventions for smoking cessation: a meta-analysis of randomized controlled trials. Eur Heart J 2009, 30:718–730.CrossRefPubMedGoogle Scholar
  11. 11.
    Clarke PB: Nicotine dependence—mechanisms and therapeutic strategies. Biochem Soc Symp 1993, 59:83–95.PubMedGoogle Scholar
  12. 12.
    Physicians’ Desk Reference. Montvale, NJ: Medical Economics Data; 2010.Google Scholar
  13. 13.
    Choi JH, Dresler CM, Norton MR, Strahs KR: Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 2003, 5:635–644.CrossRefPubMedGoogle Scholar
  14. 14.
    Shiffman S, Fant RV, Buchhalter AR, et al.: Nicotine delivery systems. Expert Opin Drug Deliv 2005, 2:563–577.CrossRefPubMedGoogle Scholar
  15. 15.
    Kaufmann V, Jepson C, Rukstalis M, et al.: Subjective effects of an initial dose of nicotine nasal spray predict treatment outcome. Psychopharmacology (Berl) 2004, 172:271–276.CrossRefGoogle Scholar
  16. 16.
    Tonnesen P, Norregaard J, Mikkelsen K, et al.: A double-blind trial of a nicotine inhaler for smoking cessation. JAMA 1993, 269:1268–1271.CrossRefPubMedGoogle Scholar
  17. 17.
    Mooney ME, Sofuoglu M: Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev Neurother 2006, 6:965–981.CrossRefPubMedGoogle Scholar
  18. 18.
    Hays JT, Ebbert JO: Bupropion sustained release for treatment of tobacco dependence. Mayo Clin Proc 2003, 78:1020–1024; quiz 1024.CrossRefPubMedGoogle Scholar
  19. 19.
    Hughes JR, Stead LF, Lancaster T: Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007, 1:CD000031.PubMedGoogle Scholar
  20. 20.
    Rollema H, Hajos M, Seymour PA, et al.: Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol 2009, 78:813–824.CrossRefPubMedGoogle Scholar
  21. 21.
    • Sofuoglu M, Herman AI, Mooney M, Waters AJ: Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. Psychopharmacology (Berl) 2009, 207:153–162. Varenicline is a first-line treatment for smoking cessation, but its exact mechanism of action has not been elucidated. This study examined how varenicline affects the physiologic, subjective, and cognitive-enhancing responses to pure nicotine, administered intravenously, in male and female smokers.CrossRefGoogle Scholar
  22. 22.
    Niaura R, Hays JT, Jorenby DE, et al.: The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin 2008, 24:1931–1941.CrossRefPubMedGoogle Scholar
  23. 23.
    Prochazka AV, Weaver MJ, Keller RT, et al.: A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998, 158:2035–2039.CrossRefPubMedGoogle Scholar
  24. 24.
    Hall SM, Reus VI, Munoz RF, et al.: Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998, 55:683–690.CrossRefPubMedGoogle Scholar
  25. 25.
    Frishman WH: Smoking cessation pharmacotherapy. Ther Adv Cardiovasc Dis 2009, 3:287–308.CrossRefPubMedGoogle Scholar
  26. 26.
    Gourlay SG, Stead LF, Benowitz NL: Clonidine for smoking cessation. Cochrane Database Syst Rev 2004, 3:CD000058.PubMedGoogle Scholar
  27. 27.
    Glassman AH, Covey LS, Dalack GW, et al.: Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther 1993, 54:670–679.CrossRefPubMedGoogle Scholar
  28. 28.
    • Piper ME, Smith SS, Schlam TR, et al.: A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry 2009, 66:1253–1262. Few research studies have investigated the relative efficacies of multiple smoking cessation pharmacotherapies. This study compared the efficacy of five smoking cessation pharmacotherapies in a placebo-controlled clinical trial. After correcting for multiple comparisons, the only medication that was more effective than others was the combination of the nicotine patch and nicotine lozenge.CrossRefPubMedGoogle Scholar
  29. 29.
    Sweeney CT, Fant RV, Fagerstrom KO, et al.: Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs 2001, 15:453-467.CrossRefPubMedGoogle Scholar
  30. 30.
    •• Hall SM, Prochaska JJ: Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings. Annu Rev Clin Psychol 2009, 5:409–431. In the United States, more than 30% of smokers have psychiatric comorbidity. However, there is limited information to guide clinicians on how best to treat tobacco addiction in this population. The authors reviewed the literature of how best to integrate smoking cessation into mental health and addiction settings.CrossRefPubMedGoogle Scholar
  31. 31.
    Colton CW, Manderscheid RW: Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006, 3:A42.PubMedGoogle Scholar
  32. 32.
    Tsoh JY, Humfleet GL, Munoz RF, et al.: Development of major depression after treatment for smoking cessation. Am J Psychiatry 2000, 157:368–374.CrossRefPubMedGoogle Scholar
  33. 33.
    Prochaska JJ, Hall SM, Tsoh JY, et al.: Treating tobacco dependence in clinically depressed smokers: effect of smoking cessation on mental health functioning. Am J Public Health 2008, 98:446–448.CrossRefPubMedGoogle Scholar
  34. 34.
    Evins AE, Cather C, Culhane MA, et al.: A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol 2007, 27:380–386.CrossRefPubMedGoogle Scholar
  35. 35.
    George TP, Vessicchio JC, Sacco KA, et al.: A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry 2008, 63:1092–1096.CrossRefPubMedGoogle Scholar
  36. 36.
    Prochaska JJ, Delucchi K, Hall SM: A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J Consult Clin Psychol 2004, 72:1144–1156.CrossRefPubMedGoogle Scholar
  37. 37.
    Joseph AM, Willenbring ML, Nugent SM, Nelson DB: A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. J Stud Alcohol 2004, 65:681–691.PubMedGoogle Scholar
  38. 38.
    Mooney ME, Poling J, Gonzalez G, et al.: Preliminary study of buprenorphine and bupropion for opioid-dependent smokers. Am J Addict 2008, 17:287–292.CrossRefPubMedGoogle Scholar
  39. 39.
    Poling J, Rounsaville BJ, Gonsai K, et al.: The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study. Am J Addict 2010 (in press).Google Scholar
  40. 40.
    Tong VT, Jones JR, Dietz PM, et al.: Trends in smoking before, during, and after pregnancy—Pregnancy Risk Assessment Monitoring System (PRAMS), United States, 31 sites, 2000–2005. MMWR Surveill Summ 2009, 58:1–29.Google Scholar
  41. 41.
    Colman GJ, Joyce T: Trends in smoking before, during, and after pregnancy in ten states. Am J Prev Med 2003, 24:29–35.CrossRefPubMedGoogle Scholar
  42. 42.
    DiFranza JR, Aligne CA, Weitzman M: Prenatal and postnatal environmental tobacco smoke exposure and children’s health. Pediatrics 2004, 113:1007–1015.PubMedGoogle Scholar
  43. 43.
    • Oncken CA, Kranzler HR: What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy? Nicotine Tob Res 2009, 11:1265–1273. This is a comprehensive review of pharmacotherapy for smoking cessation during pregnancy. In the United States, about 13% of women smoke during pregnancy. Smoking during pregnancy is associated with several health risks to the mother and the fetus, emphasizing the need for effective treatments for pregnant women.CrossRefPubMedGoogle Scholar
  44. 44.
    Park ER, Chang Y, Quinn V, et al.: The association of depressive, anxiety, and stress symptoms and postpartum relapse to smoking: a longitudinal study. Nicotine Tob Res 2009, 11:707–714.CrossRefPubMedGoogle Scholar
  45. 45.
    Marshall L, Schooley M, Ryan H, et al.: Youth tobacco surveillance—United States, 2001–2002. MMWR Surveill Summ 2006, 55:1–56.PubMedGoogle Scholar
  46. 46.
    Everett SA, Warren CW, Sharp D, et al.: Initiation of cigarette smoking and subsequent smoking behavior among U.S. high school students. Prev Med 1999, 29:327–333.CrossRefPubMedGoogle Scholar
  47. 47.
    Sussman S, Sun P, Dent CW: A meta-analysis of teen cigarette smoking cessation. Health Psychol 2006, 25:549–557.CrossRefPubMedGoogle Scholar
  48. 48.
    Lawrence D, Mitrou F, Zubrick SR: Smoking and mental illness: results from population surveys in Australia and the United States. BMC Public Health 2009, 9:285.CrossRefPubMedGoogle Scholar
  49. 49.
    Hughes JR: Motivating and helping smokers to stop smoking. J Gen Intern Med 2003, 18:1053–1057.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Psychiatry, VA Connecticut Healthcare SystemYale UniversityWest HavenUSA

Personalised recommendations